PL2176664T3 - Ccr4 jako marker nowotworowy - Google Patents

Ccr4 jako marker nowotworowy

Info

Publication number
PL2176664T3
PL2176664T3 PL08806315T PL08806315T PL2176664T3 PL 2176664 T3 PL2176664 T3 PL 2176664T3 PL 08806315 T PL08806315 T PL 08806315T PL 08806315 T PL08806315 T PL 08806315T PL 2176664 T3 PL2176664 T3 PL 2176664T3
Authority
PL
Poland
Prior art keywords
ccr4
cancer marker
marker
cancer
Prior art date
Application number
PL08806315T
Other languages
English (en)
Polish (pl)
Inventor
Frances Balkwill
Violet Slettenaar
Julia Wilson
Yaohe Wang
Tiziana Schioppa
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2176664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of PL2176664T3 publication Critical patent/PL2176664T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/575—
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL08806315T 2007-09-18 2008-09-18 Ccr4 jako marker nowotworowy PL2176664T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
EP08806315.1A EP2176664B1 (en) 2007-09-18 2008-09-18 Ccr4 as cancer marker

Publications (1)

Publication Number Publication Date
PL2176664T3 true PL2176664T3 (pl) 2014-04-30

Family

ID=38670078

Family Applications (3)

Application Number Title Priority Date Filing Date
PL08806315T PL2176664T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako marker nowotworowy
PL12182790.1T PL2533047T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako cel terapeutyczny dla nowotworu
PL12183760T PL2535716T3 (pl) 2007-09-18 2008-09-18 Marker nowotworowy i cel terapeutyczny

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL12182790.1T PL2533047T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako cel terapeutyczny dla nowotworu
PL12183760T PL2535716T3 (pl) 2007-09-18 2008-09-18 Marker nowotworowy i cel terapeutyczny

Country Status (11)

Country Link
US (2) US9134293B2 (enExample)
EP (3) EP2535716B1 (enExample)
JP (2) JP5774309B2 (enExample)
AU (1) AU2008300413B2 (enExample)
CA (1) CA2699702C (enExample)
DK (3) DK2176664T3 (enExample)
ES (3) ES2588507T3 (enExample)
GB (1) GB0718167D0 (enExample)
PL (3) PL2176664T3 (enExample)
RU (2) RU2529797C2 (enExample)
WO (1) WO2009037454A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
EP2580348B1 (en) * 2010-06-14 2018-04-25 Qiagen GmbH Method for determination of target cells or tissue for extraction of biomolecules from non-formalin-fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
WO2013063130A1 (en) * 2011-10-24 2013-05-02 Metasignal Therapeutics Inc. Carbonic anhydrase ix-related markers and use thereof
PL2785692T3 (pl) 2011-12-01 2018-02-28 Chemocentryx, Inc. Podstawione aniliny jako antagoniści ccr(4)
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
SI3065774T1 (sl) * 2013-11-06 2021-11-30 Janssen Biotech, Inc. Protitelesa proti CCL17
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
RU2740254C2 (ru) * 2014-10-01 2021-01-12 Сфинготек Гмбх ОПРЕДЕЛЕНИЕ hGH ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ТЯЖЕЛОГО НЕБЛАГОПРИЯТНОГО СЕРДЕЧНО-СОСУДИСТОГО ЯВЛЕНИЯ ИЛИ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ У ИНДИВИДУУМА
EP3283886B1 (en) * 2015-04-17 2020-01-15 Eisai Inc. Methods for treating lung cancer
WO2017017283A1 (en) 2015-07-30 2017-02-02 Qiagen Gmbh Method of preparing a frozen biological sample
TW202134282A (zh) 2015-12-02 2021-09-16 美商艾吉納斯公司 抗體和使用彼之方法
EP3626269A4 (en) 2017-05-19 2021-03-03 Shingo Maeda METHOD FOR INFILTRATION OF REGULATORY T-CELLS USING CCR4 INHIBITION AND METHOD FOR TREATMENT OF NEOPLASTIC DISEASES IN DOGS
SG11202101454PA (en) 2018-08-29 2021-03-30 Chemocentryx Inc Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JPH08507927A (ja) * 1993-03-19 1996-08-27 ザ・ジョーンズ・ホプキンス・ユニバーシティ Ａｐｃ遺伝子の変異決定用抗体およびアッセイ
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
DE60134962D1 (de) 2000-03-03 2008-09-04 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
EP1326617B9 (en) 2000-10-18 2006-10-25 Schering Aktiengesellschaft Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma
US20020182624A1 (en) * 2001-02-28 2002-12-05 Eos Biotechnology, Inc. Chemokine receptors and disease
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
US20050101530A1 (en) 2001-08-10 2005-05-12 Topigen Pharmaceutique, Inc. Cellular virus receptors and methods of use
WO2003018635A1 (fr) 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Anticorps greffes cdr humains et fragments de ces anticorps
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
AU2003291549A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
JPWO2005035582A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 Ｃｃｒ４に特異的に結合する抗体組成物
AU2004294842B2 (en) 2003-12-04 2010-05-13 Kyowa Kirin Co., Ltd. Medicine containing genetically modified antibody against chemokine receptor CCR4
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1984501B1 (en) 2006-02-14 2011-05-18 Noxxon Pharma AG Mcp-i binding nucleic acids
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
PL2535716T3 (pl) 2017-06-30
EP2176664A2 (en) 2010-04-21
WO2009037454A3 (en) 2009-05-07
DK2535716T3 (en) 2017-02-13
US10261099B2 (en) 2019-04-16
EP2535716B1 (en) 2016-11-02
PL2533047T3 (pl) 2016-11-30
EP2176664B1 (en) 2013-11-06
RU2010123921A (ru) 2011-12-20
GB0718167D0 (en) 2007-10-31
RU2014128513A (ru) 2016-02-10
EP2535716A3 (en) 2013-03-13
RU2529797C2 (ru) 2014-09-27
EP2533047A1 (en) 2012-12-12
DK2176664T3 (da) 2014-01-20
EP2535716A2 (en) 2012-12-19
ES2443541T3 (es) 2014-02-19
EP2533047B1 (en) 2016-05-11
JP6234967B2 (ja) 2017-11-22
ES2612690T3 (es) 2017-05-18
WO2009037454A2 (en) 2009-03-26
US20100278844A1 (en) 2010-11-04
US20160223572A1 (en) 2016-08-04
JP5774309B2 (ja) 2015-09-09
CA2699702C (en) 2018-03-06
AU2008300413A1 (en) 2009-03-26
JP2015212703A (ja) 2015-11-26
AU2008300413B2 (en) 2014-09-11
US9134293B2 (en) 2015-09-15
CA2699702A1 (en) 2009-03-26
DK2533047T3 (en) 2016-08-22
ES2588507T3 (es) 2016-11-03
JP2010539508A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
PL2176664T3 (pl) Ccr4 jako marker nowotworowy
EP2115162A4 (en) Adrb2 cancer markers
EP2170350A4 (en) SUBSTITUTED IMIDAZOHETEROCYCLES
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
PT2115472E (pt) Biomarcadores de cancro
EP2226315A4 (en) 2-aminoquinazoline DERIVATIVE
BRPI0813500A2 (pt) Compostos antivirais
BRPI0821086A2 (pt) Compostos inseticidas
DK2152885T3 (da) Polynukleotidmarkører
DK2132326T3 (da) Fremgangsmåder
BRPI0811264A2 (pt) Compostos
DK2190837T3 (da) 4-pyrimidinsulfamid-derivat
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
CY2022026I2 (el) Συμπλοκα πρωτεϊνων-πολυμερων
BRPI0815181A2 (pt) Compostos
ATE546446T1 (de) 5-aminocyclylmethyl-oxazolidin-2-eins-derivativ
EP2202090A4 (en) MECHANICAL PIN
CR9342S (es) Regadera
BRPI0818645A2 (pt) Lápis
BRPI0816705A2 (pt) Derivatido de 6-pirimidinil-pirimid-2-ona
BRPI0814613A2 (pt) Compostos
LT3825306T (lt) Morfinano junginiai
EP2157084A4 (en) 5-phenyl-3-pyridazinone derivative
BRPI0820430A2 (pt) Composto